ENDRA Life Sciences Inc. (NASDAQ:NDRA) Short Interest Update

ENDRA Life Sciences Inc. (NASDAQ:NDRA) saw a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 24,000 shares, a decline of 96.7% from the October 15th total of 717,700 shares. Based on an average daily trading volume, of 316,200 shares, the short-interest ratio is presently 0.1 days. Currently, 4.6% of the shares of the company are sold short.

ENDRA Life Sciences Trading Down 5.3 %

NDRA stock traded down $0.32 during trading on Wednesday, hitting $5.73. The company had a trading volume of 52,372 shares, compared to its average volume of 98,000. The firm has a market capitalization of $2.83 million, a price-to-earnings ratio of 0.00 and a beta of 0.74. The business has a 50 day moving average of $8.15 and a 200 day moving average of $7,616.00. ENDRA Life Sciences has a fifty-two week low of $5.23 and a fifty-two week high of $4,882.50.

ENDRA Life Sciences (NASDAQ:NDRA) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($140.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($122.50) by ($17.50). As a group, equities analysts predict that ENDRA Life Sciences will post -387.41 EPS for the current year.

About ENDRA Life Sciences

ENDRA Life Sciences Inc develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.